|Videos|December 27, 2022
Scynexis CEO talks recent ibrexafungerp approval
Author(s)Morgan Ebert
Marco Taglietti, MD, president and CEO of Scynexis, sits with Contemporary OB/GYN® to discuss the recent approval of ibrexafungerp (Brexafemme) for the reduction in incidence of recurrent vulvovaginal candidiasis.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
TMP-SMX linked to higher UTI treatment failure in postmenopausal women vs. nitrofurantoin and fosfomycin
2
HCV testing and postpartum treatment gaps persist among pregnant women with opioid use disorder
3
Jeff Andrews, MD, on raising awareness and identifying candidates for HPV self-collection
4
Liz Miracle, PT, on benefits of virtual pelvic floor physical therapy
5